ArticleJournal of global health2026
The risk factors of future exacerbations and treatment responses among different inhalation therapies of patients with preserved ratio impaired spirometry.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for future exacerbations in patients with COPD treated with dual LABA/LAMA.Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preserved ratio impaired spirometry (PRISm) is closely related to chronic obstructive pulmonary disease (COPD). However, there is a lack of relevant research on the treatment of patients with PRISm. Therefore, this study aimed to investigate the risk factors of future exacerbations and treatment responses among different inhalation therapies of patients with PRISm. Methods: This is a retrospective cohort study. Patients with PRISm were registered in the real-world study on the status of diagnosis and treatment of COPD (RealDTC) study between January 2017 and August 2024. Data on demographics, pulmonary function, symptom scores, number of exacerbations and hospitalisations in the past year, inhalation therapy regimens including long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS, and comorbidities were collected. The number of exacerbations, frequent exacerbations, hospitalisations, and all-cause of mortality were collected during one year of follow-up. Results: A total of 575 patients were included for the final analysis. During one year of follow-up, 144 (25.0%) patients experienced exacerbations. The patients experienced exacerbations had higher age, symptom score, number of exacerbations and hospitalisations in the past year, as well as higher proportion of biofuel exposure and without inhalation therapy. Logistic regression analysis showed that age, number of hospitalisations in the past year, and without inhalation therapy were the independent risk factors for patients experienced exacerbations. Furthermore, after propensity score matching, the patients without inhalation therapy had higher number of exacerbations, frequent exacerbations, and hospitalisations during one year of follow-up. However, there were no significant differences in future exacerbations, frequent exacerbations, hospitalisations, and all-cause of mortality among LAMA, LABA + LAMA, LABA + ICS, and LABA + LAMA + ICS. Conclusions: Patients with PRISm had high risk of future exacerbations. Inhalation therapy could reduce the risk of future exacerbations and clinicians should recommend mono-LAMA to patients with this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.